Risk Factors for Predicting Severe Neutropenia Induced by Amrubicin in Patients with Advanced Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|58|6|419-425

ISSN： 0009-3157

Source： Chemotherapy, Vol.58, Iss.6, 2013-01, pp. : 419-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 3, 2015-03 ,pp. : 180-184

Karger

Access to resources Recommend Favorite

Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-09 ,pp. : 99-105

Karger

Access to resources Recommend Favorite

Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 215-224

Karger

Access to resources Recommend Favorite

Prospective Study of Empiric Monotherapy with Ceftazidime for Low-Risk Grade IV Febrile Neutropenia after Cytotoxic Chemotherapy in Cancer Patients

By  

Chemotherapy, Vol. 52, Iss. 4, 2006-06 ,pp. : 185-189

Karger

Access to resources Recommend Favorite

Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer

By  

Chemotherapy, Vol. 61, Iss. 5, 2016-04 ,pp. : 256-261

Karger

Access to resources Recommend Favorite